Osimertinib is a kinase inhibitor, which falls under this category of targeted therapy as it targets EGFR gene, thereby halting carcinogenesis in NSCLC patients with a mutation in EGFR gene. This evidence concerns the gene EGFR and non-small cell lung carcinoma.